Hold Abbott India Ltd For Target Rs.20315 - ICICI Direct
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Numbers miss despite decent growth in power brands…
About the stock: Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among others.
* Some top brands- Thyronorm, Udiliv, Duphalac, Duphaston, Cremafin Plus and Veritn have been the growth drivers besides new launches
* Abbott has 140+ brands in segments of women’s health, gastroenterology, metabolics, CNS, multi-specialty, vaccines & consumer health
Q4FY23 Results: Numbers were below estimates across all fronts.
* Revenues increased 7% YoY to | 1343 crore
* EBITDA de-grew 4.7% YoY to | 280 crore while EBITDA margins declined 256 bps to 20.9%
* PAT increased 9.5 % YoY to ~| 231 crore
What should investors do? Abbott’s share price has grown at 7.9% CAGR over the past three years.
* We maintain HOLD rating as valuations at current levels largely factor in power brands growth momentum and growing traction for the new brands
Target Price and Valuation: Valued at | 20875 i.e. 36x FY25E EPS of | 564.3
Key triggers for future price performance:
* Focus on new launches, which is consistent (+100 launches and line extensions in the last 10 years). Target for the next five year- ~75 launches
* Performances of legacy Novo Nordisk and Abbott Healthcare products for which the company has a marketing tie-up
* The company is looking for generic opportunities in India for products loosing patent exclusivity in India over the next five years
* Focus on marketing and patient awareness programmes especially in tier IIVI cities
Alternate Stock Idea: Besides Abbott, in our healthcare coverage we like P&G Health.
* P&G Health is a leading pharma cum OTC company with key focus on vitamins, minerals, supplement (VMS). Its recent earnings reflect sustained efforts to regain momentum via improved mix and productivity initiatives
* BUY with a target price of | 5620
To Read Complete Report & Disclaimer Click Here
For More ICICI Securities Disclaimer https://www.icicisecurities.com/AboutUs.aspx About=7
Above views are of the author and not of the website kindly read disclaime
